Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT02085668
Other study ID # RE-ADAPT-HF
Secondary ID CIV-13-10-011660
Status Withdrawn
Phase N/A
First received
Last updated
Start date May 2014
Est. completion date May 2019

Study information

Verified date May 2023
Source Universität des Saarlandes
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of the trial is to investigate the safety and effectiveness of renal denervation for the treatment of chronic heart failure (CHF).


Description:

Heart failure is a major public health problem. It is associated with high mortality, frequent hospitalization and represents a large cost to the health care system. Therapies to ameliorate the high mortality and morbidity of heart failure have focused on abrogation of activated neurohormonal systems associated with this condition. These systems include the renin-angiotensin-aldosterone system and the sympathetic nervous system. Strategies to ameliorate sympathetic activation have primarily focused on blockade of the beta-adrenoceptors that mediate the adverse effects of activation of this system upon the myocardium. This has been a highly successful strategy with beta-blockers resulting in an approximately 35% reduction in mortality as well as improvements in hospitalization and quality of life and attenuation of disease progression. However, less than full blockade of the effects of the sympathetic nervous system is achieved with the use of conventional doses of beta-blockers. Moreover, a not insignificant fraction of patients are unable to tolerate beta-blockers or are not able to have them up-titrated to target effective doses, in large part because of the systemic nature of these agents, whereas renal denervation allows the selective removal of the kidney's contribution to central sympathetic drive without blunting other compensatory mechanisms. The renin-angiotensin-aldosterone axis has also been found to be a key system involved in heart failure disease progression and it too may be inhibited by renal sympathetic denervation. Therefore, a clear need exists for further strategies to beneficially manipulate the sympathetic activation that is characteristic of the heart failure disease process. Cardiorenal syndrome is a major comorbid condition of patients with advanced chronic heart failure. In the setting of renal hypoperfusion and/or activation of neurohormonal and cytokine systems there is a reduction in glomerulofiltration. Renal function has been found to be a major determine of prognosis in these patients. Strategies to ameliorate cardiorenal syndrome are being actively pursued. There is considerable a priori evidence to suggest that the sympathetic nervous system, in particular renal sympathetic, is a key factor to the progression of cardiorenal syndrome and impaired tubulo-glomerular feedback. In particular renal sympathetics reduce renal perfusion through vascular alpha adrenergic receptor stimulation as well as, indirectly, through stimulation of local release of adenosine causing afferent glomerular arteriole constriction. We hypothesize that by disrupting renal sympathetic afferent and efferent activity these salutary adenosine inhibitory mediated effects will be demonstrated using the renal denervation approach. A number of studies with hypertension patients indicate that the Symplicity Catheter System can safely denervate the kidney without significant periprocedural complications. In a small first-in man pilot study, involving seven normotensive patients with chronic heart failure, six months after renal denervation their 6-min walk distance improved significantly and the patients' self-assessment of well-being also improved. No procedural or post procedural complications following renal denervation in patients in 6 months of intensive follow-up were found. The investigators believe that therapeutic renal denervation using the Symplicity Catheter is a promising therapy for patients with elevated sympathetic activity, as in CHF.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date May 2019
Est. primary completion date December 2015
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - New York Heart Association Class II-III symptoms of chronic heart failure - Systolic left ventricular dysfunction as assessed by echocardiogram with left ventricular ejection fraction in a range of 10%- 40%. - GFR >30 mL/min/1.73m2 - Brain natriuretic Peptide (BNP) >100 pg/ml or N terminal (NT)-Pro-BNP >400 pg/ml. - Optimal medical therapy according to current guidelines for CHF management. Treatment for HF must be stable (including drug and dose) for at least 4 weeks prior to procedure, with the exception of diuretics, where stability is required for at least 2 weeks. - others Exclusion Criteria: - Renal arterial anatomy that is ineligible for treatment - CHF caused by pericarditis or by acute myocarditis or by endocrine diseases. - Myocardial infarction, unstable angina pectoris, or a cerebrovascular accident within three 12 weeks of the screening visit. - Office systolic BP at screening less than 90 mmHg - Primary pulmonary hypertension. - Clinically significant cardiac structural valvular disease, unless corrected by a properly functional prosthetic valve - Major surgery, including bariatric surgery, in the previous 12 weeks before baseline. - Contrast media administration in the previous 30 days before baseline. - Known hypersensitivity to material of the Symplicity Catheter. - Inpatient hospitalization for decompensated HF in the previous 60 days before baseline. - others

Study Design


Intervention

Device:
Renal denervation (Symplicity™)
Delivery of radiofrequency through the wall of the renal artery to disrupt the surrounding renal nerves under angiography control

Locations

Country Name City State
Austria Paracelsus Medical University Salzburg
Germany University Heart Center Freiburg Bad Krozingen Bad Krozingen
Germany German Heart Institute Berlin Berlin
Germany University Hospital Bonn Bonn
Germany University Hospital Gießen Marburg Gießen
Germany University Hospital Heidelberg Heidelberg
Germany University Hospital Saarland Homburg/Saar
Germany University of Leipzig, Heart Center Leipzig
Germany University Hospital Tübingen Tübingen
Sweden Sahlgrenska University Hospital Gothenburg
Switzerland University Hospital Zurich Zürich

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Saarland

Countries where clinical trial is conducted

Austria,  Germany,  Sweden,  Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety of renal denervation with the Symplicity Catheter System with special consideration of clinically significant periprocedural adverse events in CHF patients Number of complications associated with the delivery and/or use of the Symplicity Catheter (e.g., vascular injury and bleeding complications, access site hematoma, etc.).
Vital signs, blood and urine measurements taken before, during and after the denervation procedure
Baseline visit for treatment group, month 6 visit for control group
Secondary Physiologic response to renal denervation: ventricular function Measured by echocardiography at 6 months From denervation prodecure to 6 months after renal denervation procedure
Secondary Physiologic Response to renal denervation: renal function Calculated by glomerular filtration rate (GFR) at 6 months From denervation prodecure to 6 months after renal denervation procedure
Secondary Physiologic Response to renal denervation: symptomatology/Quality of Life Measured by EuroQol - 5 dimensions (EQ-5D) and by Kansas City Cardiomyopathy questionnaires at 6 months after renal denervation From denervation prodecure to 6 months after renal denervation procedure
Secondary Physiologic Response to renal denervation: additional parameters Composite measure From denervation prodecure to 6 months after renal denervation procedure
See also
  Status Clinical Trial Phase
Completed NCT03597646 - The Effect of Kinesio Taping on Pulmonary Function and Functional Capacity in Patients With Chronic Heart Failure N/A
Terminated NCT04065997 - Apogee International
Withdrawn NCT03675113 - Effect of Upper Extremity Aerobic Exercise Training on Exercise Capacity Patients With Chronic Heart Failure N/A
Completed NCT02916160 - Sacubitril-valsartan and Heart Failure Patients : the ENTRESTO-SAS Study Phase 4
Completed NCT03126656 - Effects of Testosterone on Myocardial Repolarization Phase 4
Completed NCT02268500 - VAccination to Improve Clinical outComes in Heart Failure Trial: a Feasibility Study (VACC-HeFT) Phase 4
Completed NCT02247245 - The Influence of Heart Rate Limitation on Exercise Tolerance in Pacemaker Patients. N/A
Terminated NCT01906957 - Cognition and Exercise Training N/A
Completed NCT01919918 - Muscle Afferent Feedback Effects in Patients With Heart Failure Phase 1
Not yet recruiting NCT01669395 - Severe Heart Failure and Homebased Rehabilitation - An Intersectoral Randomized Controlled Trial N/A
Completed NCT00984529 - Evaluation of Clinical Signs and Symptoms of Chronic Heart Failure in Patients Treated With Candesartan Cilexetil in Croatia N/A
Recruiting NCT00863421 - Sleep Disordered Breathing in Patients With Chronic Heart Failure N/A
Completed NCT02840565 - Tolerability, Pharmacokinetics and Pharmacodynamics of Six Multiple Rising Dose Regimens of BIA 5-453 Phase 1
Completed NCT02441218 - Effects of Ivabradine on Cardiovascular Events in Patients With Moderate to Severe Chronic Heart Failure and Left Ventricular Systolic Dysfunction. A Three-year International Multicentre Study Phase 3
Completed NCT00149409 - Omega-3-Polyunsaturated Fatty-Acids (N3-Pufa) In Patients With Severe Chronic Heart Failure Phase 2/Phase 3
Terminated NCT05532046 - A Study to Learn How Safe Study Drug BAY2413555 is, How it Affects the Body, and How it Moves Into, Through, and Out of the Body Over 4 Weeks of Use in Participants With Heart Failure and Implanted Cardiac Defibrillator or Cardiac Resynchronization Devices (ICD/CRT) Phase 1
Recruiting NCT04984928 - Readmission Risk of Patients With Heart Failure.
Completed NCT02814097 - A Study to Evaluate the Effects of 4 Weeks Treatment With Subcutaneous Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Preserved Ejection Fraction Phase 2
Active, not recruiting NCT05560737 - ODYSSEE-vCHAT Mental Health Program for Heart Failure and Kidney Disease Patients
Recruiting NCT03286127 - Palliative Outcome Evaluation Muenster I